TY - JOUR
T1 - Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD Era
AU - Sharma, Pratima
AU - Welch, Kathy
AU - Hussain, Hero
AU - Pelletier, Shawn J.
AU - Fontana, Robert J.
AU - Marrero, Jorge
AU - Merion, Robert M.
N1 - Funding Information:
Acknowledgments Dr. Pratima Sharma was supported by an American Society of Transplantation/Roche clinical science faculty development grant for 2008 and Michigan Institute for Clinical and Health Research NIH-CTSA, UL1RR024986, Collaborative Type 2 (Bedside to community) grant. Dr. Sharma is also supported by National Institutes of Health grant KO8 DK-088946. This research was presented, in part, as a free communication at the American Transplant Congress, 2010, held in San Diego, California.
PY - 2012/3
Y1 - 2012/3
N2 - Background and Aims Deceased donor liver transplantation (DDLT) rates for candidates with hepatocellular carcinoma (HCC) have significantly increased in the MELD era because of the extra priority given to these candidates. We examined the incidence and pre-DDLT radiological and donor factors associated with post-DDLT HCC recurrence in the MELD era. Methods Outcomes of HCC candidates aged >18 years that underwent DDLT between 2/28/02 and 6/30/08 (n = 94) were reviewed. The primary outcome was biopsyproven post-LT HCC recurrence at any site. Kaplan-Meier analysis was used to calculate the cumulative incidence and Cox regression was used to identify the predictors of post-LT HCC recurrence. Results The median age of the 94 candidates who met the study criteria was 54 years, 64% had hepatitis C, median lab MELD was 13, and median pre-LT AFP was 47 ng/dl. Based upon pre-DDLT imaging, 94% candidates met the Milan criteria. The median waiting time to transplant was 47 days and 27% received pre-DDLT locoregional therapy. Seventeen (18%) developed HCC recurrence after 2.1 median years with a cumulative incidence of 6.8, 12, and 19% at 1, 2, and 3 years post- DDLT. The pre-DDLT number of lesions (p = 0.015), largest lesion diameter (p = 0.008), and higher donor age (p = 0.002) were the significant predictors of HCC recurrence after adjusting for pre-LT loco-regional therapy and waiting time. Post-LT HCC recurrence (p<0.0001) and higher donor age (p = 0.029) were associated with lower post-LT survival. Conclusions Post-LT HCC recurrence is higher in our MELD era cohort than the reported rate of 8% at 4 years in Mazzaferro et al.'s study. The risk of HCC recurrence was significantly associated with the number of lesions and size of the largest lesion at the time of DDLT as well as with older donor age. Risk stratification using a predictive model for post-LT HCC recurrence based on pre-LT imaging and donor factors may help guide candidate selection and tailoring of HCC surveillance strategies after LT.
AB - Background and Aims Deceased donor liver transplantation (DDLT) rates for candidates with hepatocellular carcinoma (HCC) have significantly increased in the MELD era because of the extra priority given to these candidates. We examined the incidence and pre-DDLT radiological and donor factors associated with post-DDLT HCC recurrence in the MELD era. Methods Outcomes of HCC candidates aged >18 years that underwent DDLT between 2/28/02 and 6/30/08 (n = 94) were reviewed. The primary outcome was biopsyproven post-LT HCC recurrence at any site. Kaplan-Meier analysis was used to calculate the cumulative incidence and Cox regression was used to identify the predictors of post-LT HCC recurrence. Results The median age of the 94 candidates who met the study criteria was 54 years, 64% had hepatitis C, median lab MELD was 13, and median pre-LT AFP was 47 ng/dl. Based upon pre-DDLT imaging, 94% candidates met the Milan criteria. The median waiting time to transplant was 47 days and 27% received pre-DDLT locoregional therapy. Seventeen (18%) developed HCC recurrence after 2.1 median years with a cumulative incidence of 6.8, 12, and 19% at 1, 2, and 3 years post- DDLT. The pre-DDLT number of lesions (p = 0.015), largest lesion diameter (p = 0.008), and higher donor age (p = 0.002) were the significant predictors of HCC recurrence after adjusting for pre-LT loco-regional therapy and waiting time. Post-LT HCC recurrence (p<0.0001) and higher donor age (p = 0.029) were associated with lower post-LT survival. Conclusions Post-LT HCC recurrence is higher in our MELD era cohort than the reported rate of 8% at 4 years in Mazzaferro et al.'s study. The risk of HCC recurrence was significantly associated with the number of lesions and size of the largest lesion at the time of DDLT as well as with older donor age. Risk stratification using a predictive model for post-LT HCC recurrence based on pre-LT imaging and donor factors may help guide candidate selection and tailoring of HCC surveillance strategies after LT.
KW - Deceased donor liver transplantation
KW - Hepatocellular carcinoma
KW - Model for end-stage liver disease
UR - http://www.scopus.com/inward/record.url?scp=84859480497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859480497&partnerID=8YFLogxK
U2 - 10.1007/s10620-011-1910-9
DO - 10.1007/s10620-011-1910-9
M3 - Article
C2 - 21953139
AN - SCOPUS:84859480497
SN - 0163-2116
VL - 57
SP - 806
EP - 812
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 3
ER -